M. Covela Rúa

First-line panitumumab plus capecitabine for the treatment of older patients with wild-type RAS metastatic colorectal cancer. The phase II, PANEL study.

M. Ramos Vázquez, A. Fernández Montes, J. M. Méndez Méndez, 2020, Journal of geriatric oncology.

FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial.

A. Fernández Montes, N. Martínez Lago, J. M. Méndez Méndez, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data

P. Jiménez-Fonseca, A. Carmona-Bayonas, M. Sánchez Cánovas, 2021, Scientific Reports.

Efficacy and safety of FOLFIRI/aflibercept in second‐line treatment of metastatic colorectal cancer in a real‐world population: Prognostic and predictive markers

A. Fernández Montes, N. Martínez Lago, J. M. Méndez Méndez, 2019, Cancer medicine.

Clear-Cell Adenocarcinoma of Vesical Origin: A Case Study of Metastatic Disease Treated with Chemotherapy

M. Constenla Figueiras, M. Covela Rúa, H. S. Suh Oh, 2010, Chemotherapy research and practice.

Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram

A. Fernández Montes, N. Martínez Lago, J. M. Méndez Méndez, 2019, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.